ABSTRACT

It will be one year since severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has created havoc andmayhem in form of coronavirus disease 2019 (COVID-19) pandemic. Many potential vaccines candidates are identified and are currently in different phases of clinical trial. The international regulatory authority has given emergency approval of two vaccines, Pfizer and BioNTech and Moderna. The Phase 3 trial of both these vaccines are still in progress and there are scattered reports of adverse effects including allergic reaction among vaccinated health care workers. The safety profile of these vaccines requires long term follow up of patients before one can assure its efficacy and clinical effectiveness.

Key Words: COVID-19, SARS-CoV-2, Vaccines.

How to cite this: Gilani RA. COVID-19 Vaccines Interim Analysis: Unanswered Questions. Life and Science. 2020; 1(suppl): 133-134. doi: http://doi.org/10.37185/LnS.1.1.179